Skip to main content

Inotuzumab Ozogamicin Approved for Pediatric Patients with Acute Lymphoblastic Leukemia

The FDA has granted approval to inotuzumab ozogamicin (Besponsa™, Pfizer) for pediatric patients one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).   Why it matters: "Among adult patients with relapsed or refractory B-ALL, the use of inotuzumab ozogamicin has led to improved outcomes as compared to those treated with chemotherapy alone," said Tristan Knight, MD, FRCPC, an Oncology Data Advisor Editorial Board Member and Clinical...

Continue reading

Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD

Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her presentation on neighborhood disadvantages associated with inferior overall survival outcomes for patients with acute myeloid leukemia (AML). In additio...

Continue reading

New and Exciting Directions in Leukemia Research, Fellows Forum With Sunil Iyer, MD

Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Sunil Iyer, Chief Hematology/Oncology Fellow at the University of Miami, Florida, discusses his leukemia research, exciting new treatment directions, and what to look forward to in the next several years regarding leukemia research.  Oncology Data Advisor: Welcome to the Oncology Data Advisor Fellows For...

Continue reading